Skin disorder known as Eczema (Atopic Dermatitis): Signs, remedies, and additional information
Atopic dermatitis, commonly known as eczema, is an inflammatory skin condition affecting millions of people in the United States, including approximately 31.6 million, which is nearly 10% of the population. This condition can cause itchy, rough patches on a person's skin, and its impact varies depending on age and skin tone.
In children, AD is most prevalent, with around 1 in 4 developing the condition, and symptoms usually appearing by the age of 5 years. Common symptoms include dry, scaly patches of skin, thickened, discolored skin, and open, crusted, or weeping sores. Children from the ages of 2 to puberty may experience rashes behind the creases of elbows or knees, on the neck, wrists, and ankles, and in the crease between the buttocks and legs.
For mild to moderate AD, topical treatments are often the first line of defence. Moisturizers are fundamental in restoring the skin barrier, while topical corticosteroids reduce inflammation and itching. Calcineurin inhibitors serve as an alternative to steroids, especially for sensitive or delicate skin areas.
Recent FDA approvals have brought promising non-steroidal topical alternatives, such as roflumilast cream 0.15% and tapinarof cream 1%. Roflumilast cream has received strong recommendations for adults and children ages 6 and older, offering a steroid-free option with good efficacy and safety. Tapinarof cream, approved for adults and children 2 years and older, rapidly reduces itching and targets inflammatory pathways to aid skin barrier restoration.
For moderate to severe AD or when topical therapy is insufficient, systemic treatments may be considered. Injectable biologics, such as dupilumab for adults and children ≥ 6 months, and tralokinumab for adults, target specific immune pathways and are given every two weeks. JAK inhibitors, taken once daily, are an option for adults and children 12 years and older with moderate to severe disease not well controlled by other systemic therapies. Oral corticosteroids may be used short term for severe flares but have significant side effects and are not recommended for long-term use. Phototherapy (UV light therapy) is another systemic option for children six and older and adults, useful for extensive or persistent disease.
It is essential to tailor treatment options individually based on disease severity, age, treatment response, and risk of side effects. Shared decision-making with healthcare providers is emphasized to optimize effectiveness and safety.
For babies under the age of 2, symptoms may include rashes on the scalp and cheeks, rashes that bubble up before leaking fluid, and extreme itchiness. Although there is currently no cure for eczema, various treatment options may help people manage their symptoms and reduce the risk of flare-ups. These may include systemic therapies, phototherapy, oral medication, topical ointments, home remedies, and learning to recognize and avoid individual eczema triggers.
Environmental factors that may bring out the symptoms of eczema include irritants (soaps, detergents, shampoos, disinfectants, juices from fresh fruits, meats, and vegetables), allergens (dust mites, pets, pollens, mold), microbes (bacteria such as Staphylococcus aureus, viruses, and certain fungi), hot and cold temperatures (very hot and very cold weather, high and low humidity, perspiration from exercise), foods (dairy products, eggs, nuts and seeds, soy products, and wheat), stress, and hormones (females may experience increased eczema symptoms when their hormone levels are changing, such as during pregnancy and at certain points in the menstrual cycle).
People with dark skin tones may experience patches of hyperpigmentation, depigmentation, or hypopigmentation. By adolescence, approximately 60% of people with AD will no longer show symptoms.
In conclusion, topical therapies remain the cornerstone for mild-to-moderate AD, with advanced systemic options available for more severe or difficult-to-treat cases in both adults and children. Recent FDA approvals of roflumilast and tapinarof creams offer promising non-steroidal topical alternatives for managing AD safely across wide age ranges. It is crucial for individuals to work closely with their healthcare providers to develop the best treatment plan for them.
- Lung health is crucial for individuals managing atopic dermatitis, or eczema, as stress can exacerbate both conditions.
- Type 2 inflammation plays a significant role in the development of eczema, similar to other medical entities like asthma and COPD.
- Obesity can contribute to the increased severity of eczema due to the associated inflammation and skin strain.
- During the early stages of life, eczema can cause dry, scaly skin on an infant's scalp and cheeks, sometimes leading to fluid-filled rashes.
- Diabetes and hormonal imbalances can also impact the progression and symptoms of eczema, particularly in females during pregnancy and certain phases of the menstrual cycle.
- Skin degeneration is not a typical symptom of eczema, but chronic inflammation may lead to thinning or aging of the skin in some cases.
- A fungal infection of skin, such as tinea corporis or dermatophytosis, may mimic the appearance of eczema or coexist with eczema, particularly in humid environments.
- Depression and anxiety are common in people with eczema due to the physical and emotional challenges the condition presents.
- For most cases of eczema, topical treatments such as moisturizers, steroids, and non-steroidal alternatives are recommended to alleviate symptoms.
- Systemic treatments like injectable biologics, JAK inhibitors, oral corticosteroids, and phototherapy are reserved for more severe cases or when topical therapies are insufficient.
- FAQs about eczema and its treatments can help individuals navigate the health-and-wellness landscape and make informed decisions for their skin-care needs.
- Aq (Actionable Quantity) and HST (Human Susceptibility Target) are terms often used in predictive science to understand the impact of environmental factors on skin conditions, including eczema.
- People with darker skin tones may face additional challenges with eczema, such as patches of hyperpigmentation, depigmentation, or hypopigmentation.
- In the macular region of the eye, eczema-related dryness or inflammation is rare, but it is essential to speak with a healthcare provider about any concerns or unusual symptoms related to eye health.
%3A%20Signs%2C%20remedies%2C%20and%20additional%20information){kind=link}